These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9704458)

  • 1. Evaluating the clinical significance of blood group alloantibodies that are causing problems in pretransfusion testing.
    Garratty G
    Vox Sang; 1998; 74 Suppl 2():285-90. PubMed ID: 9704458
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management.
    Shirey RS; Boyd JS; Parwani AV; Tanz WS; Ness PM; King KE
    Transfusion; 2002 Nov; 42(11):1435-41. PubMed ID: 12421216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is a computer crossmatch in the absence of an immediate-spin antibody screen adequate for persons identified to be at increased risk of forming new blood group antibodies?
    Sandler SG; Abedalthagafi M; Langeberg A
    Transfusion; 2008 Oct; 48(10):2265-6. PubMed ID: 18928510
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful transfusion of antigen positive blood to alloimmunised patients using a monocyte monolayer assay.
    Noumsi GT; Billingsley KL; Moulds JM
    Transfus Med; 2015 Apr; 25(2):92-100. PubMed ID: 25828731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in transfusion medicine. Prewarmed tests: pro-why, when, and how-not if.
    Mallory D
    Transfusion; 1995 Mar; 35(3):268-70. PubMed ID: 7878722
    [No Abstract]   [Full Text] [Related]  

  • 6. [Manual polybrene test versus saline test as a means of detecting alloantibodies against red cells in the pretransfusion examination].
    de Chirinos SM; Lichtiger B
    Sangre (Barc); 1991 Feb; 36(1):43-6. PubMed ID: 1853273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
    Phou S; Costello C; Kopko PM; Allen ES
    Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study.
    Evers D; Middelburg RA; de Haas M; Zalpuri S; de Vooght KM; van de Kerkhof D; Visser O; Péquériaux NC; Hudig F; Schonewille H; Zwaginga JJ; van der Bom JG
    Lancet Haematol; 2016 Jun; 3(6):e284-92. PubMed ID: 27264038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do you think that the cross match with donor red cells can be omitted when the serum of a patient has been tested for the presence of red cell alloantibodies with a cell panel?
    Vox Sang; 1982; 43(3):151-68. PubMed ID: 6815895
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythrocyte survival tests in cases of anti-AnWj antibodies.
    van Gaalen FA; Zanin DE; Brand A
    Vox Sang; 2009 Oct; 97(3):275-6. PubMed ID: 19790299
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-Vel reactivity diminished by adsorption with rabbit RBC stroma.
    Mechanic SA; Maurer JL; Igoe MJ; Kavitsky DM; Nance ST
    Transfusion; 2002 Sep; 42(9):1180-3. PubMed ID: 12430675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies in transfusion medicine. Prewarmed tests: con.
    Judd WJ
    Transfusion; 1995 Mar; 35(3):271-5. PubMed ID: 7878723
    [No Abstract]   [Full Text] [Related]  

  • 13. How concerned should we be about missing antibodies to low incidence antigens?
    Garratty G
    Transfusion; 2003 Jul; 43(7):844-7. PubMed ID: 12823741
    [No Abstract]   [Full Text] [Related]  

  • 14. [Management of feto-maternal red cell allo-immunizations].
    Bricca P; Guinchard E; Guitton Bliem C
    Transfus Clin Biol; 2011 Apr; 18(2):269-76. PubMed ID: 21397546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three low-ionic-strength solutions for routine pretransfusion testing: antibody screening/identification, cross-matching, immune anti-ABO detection, and direct antiglobulin tests.
    Kaspi E; Mallié F; Gouvitsos J; Dettori I; Chiaroni J; Ferrera V
    Transfusion; 2009 Dec; 49(12):2772-3. PubMed ID: 20163691
    [No Abstract]   [Full Text] [Related]  

  • 16. [Difficulties of the care of public antigen alloimmunization].
    Ben Amor I; Rekik T; Louati N; Lahiani W; Rekik H; Peyrard T; Menif H; Gargouri J
    Transfus Clin Biol; 2016 May; 23(2):103-5. PubMed ID: 26826911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies of undetermined significance: nuisance or near miss?
    Tormey CA; Hendrickson JE
    Transfusion; 2013 May; 53(5):926-8. PubMed ID: 23659526
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody of undetermined specificity: frequency, laboratory features, and natural history.
    Liu C; Grossman BJ
    Transfusion; 2013 May; 53(5):931-8. PubMed ID: 23305295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Problem-solving in immunohematology: direct compatibility laboratory test ].
    Mannessier L; Roubinet F; Chiaroni J
    Transfus Clin Biol; 2001 Dec; 8(6):481-4. PubMed ID: 11802611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irregular agglutinins and the compatibility test: the elements of choice].
    Rouger P; Salmon C
    Rev Fr Transfus Immunohematol; 1983 Feb; 26(1):5-13. PubMed ID: 6407087
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.